Diabetes drug tested to protect the heart from scarring
NCT ID NCT05367063
Summary
This study investigated whether the diabetes medication canagliflozin could reduce harmful scarring in the heart muscle of people with type 2 diabetes who are at high risk for heart disease. Researchers used special heart scans to measure scarring in 45 participants before and after treatment. The goal was to understand if this drug's known heart benefits work by preventing this type of heart damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.